FTO
FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Overview
RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis. Specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes. M6A demethylation by FTO affects mRNA expression and stability.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 1.00, genetic association 0.77, clinical 0.16).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
- 1 · What it is
FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
- 2 · What goes wrong in cancer
RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis.
- 3 · How drugs use it
No product in this corpus aims at FTO yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:24678 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9C0B1 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000140718 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: breast cancer 0.61 (GraphQL API, CC0))
Biology
RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis. Specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes. M6A demethylation by FTO affects mRNA expression and stability. Also able to demethylate m6A in U6 small nuclear RNA (snRNA). Mediates demethylation of N(6),2'-O-dimethyladenosine cap (m6A(m)), by demethylating the N(6)-methyladenosine at the second transcribed position of mRNAs and U6 snRNA. Demethylation of m6A(m) in the 5'-cap by FTO affects mRNA stability by promoting susceptibility to decapping. Location: Nucleus; Nucleus speckle; Cytoplasm (UniProt). Locus 16q12.2 (HGNC).
- Breast cancer: Open Targets association 0.61 with breast cancer (MONDO_0007254)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.16. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FTO" OR ABSTRACT:"FTO" OR TITLE:"FTO alpha-ketoglutarate dependent dioxygenase" OR ABSTRACT:"FTO alpha-ketoglutarate dependent dioxygenase" OR TITLE:"Alpha-ketoglutarate-dependent dioxygenase FTO" OR ABSTRACT:"Alpha-ketoglutarate-dependent dioxygenase FTO" OR TITLE:"KIAA1752" OR ABSTRACT:"KIAA1752" OR TITLE:"MGC5149" OR ABSTRACT:"MGC5149" OR TITLE:"ALKBH9" OR ABSTRACT:"ALKBH9") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FTO, not a curated reading list.